120 related articles for article (PubMed ID: 22797580)
1. Targeting intracerebral inflammation in multiple sclerosis: is it feasible?
Lassmann H
Acta Neuropathol; 2012 Sep; 124(3):395-6. PubMed ID: 22797580
[No Abstract] [Full Text] [Related]
2. Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.
van Doorn R; Nijland PG; Dekker N; Witte ME; Lopes-Pinheiro MA; van het Hof B; Kooij G; Reijerkerk A; Dijkstra C; van van der Valk P; van Horssen J; de Vries HE
Acta Neuropathol; 2012 Sep; 124(3):397-410. PubMed ID: 22810490
[TBL] [Abstract][Full Text] [Related]
3. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.
Miron VE; Ludwin SK; Darlington PJ; Jarjour AA; Soliven B; Kennedy TE; Antel JP
Am J Pathol; 2010 Jun; 176(6):2682-94. PubMed ID: 20413685
[TBL] [Abstract][Full Text] [Related]
4. Fingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis.
Nishihara H; Shimizu F; Sano Y; Takeshita Y; Maeda T; Abe M; Koga M; Kanda T
PLoS One; 2015; 10(3):e0121488. PubMed ID: 25774903
[TBL] [Abstract][Full Text] [Related]
5. The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulation.
Haghikia A; Gold R
Am J Pathol; 2010 Jun; 176(6):2599-601. PubMed ID: 20395429
[TBL] [Abstract][Full Text] [Related]
6. Targeting the immune system in intracerebral hemorrhage.
Sheth KN; Rosand J
JAMA Neurol; 2014 Sep; 71(9):1083-4. PubMed ID: 25004375
[No Abstract] [Full Text] [Related]
7. Investigation of immune and CNS-mediated effects of fingolimod in the focal delayed-type hypersensitivity multiple sclerosis model.
Anthony DC; Sibson NR; Losey P; Meier DP; Leppert D
Neuropharmacology; 2014 Apr; 79():534-41. PubMed ID: 24412675
[TBL] [Abstract][Full Text] [Related]
8. Fingolimod for multiple sclerosis.
Pelletier D; Hafler DA
N Engl J Med; 2012 Jan; 366(4):339-47. PubMed ID: 22276823
[No Abstract] [Full Text] [Related]
9. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
Tar L; Vécsei L
Ideggyogy Sz; 2012 Mar; 65(3-4):83-100. PubMed ID: 23136726
[TBL] [Abstract][Full Text] [Related]
10. Blocking lymphocyte trafficking with FTY720 prevents inflammation-sensitized hypoxic-ischemic brain injury in newborns.
Yang D; Sun YY; Bhaumik SK; Li Y; Baumann JM; Lin X; Zhang Y; Lin SH; Dunn RS; Liu CY; Shie FS; Lee YH; Wills-Karp M; Chougnet CA; Kallapur SG; Lewkowich IP; Lindquist DM; Murali-Krishna K; Kuan CY
J Neurosci; 2014 Dec; 34(49):16467-81. PubMed ID: 25471584
[TBL] [Abstract][Full Text] [Related]
11. A multiple sclerosis drug sheds light on astrocyte biology.
Davletov B
Acta Physiol (Oxf); 2014 Sep; 212(1):8-10. PubMed ID: 24947320
[No Abstract] [Full Text] [Related]
12. Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.
Colombo E; Di Dario M; Capitolo E; Chaabane L; Newcombe J; Martino G; Farina C
Ann Neurol; 2014 Sep; 76(3):325-37. PubMed ID: 25043204
[TBL] [Abstract][Full Text] [Related]
13. Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis.
di Nuzzo L; Orlando R; Nasca C; Nicoletti F
Drug Des Devel Ther; 2014; 8():555-68. PubMed ID: 24876766
[TBL] [Abstract][Full Text] [Related]
14. Targeting synaptic pathology in multiple sclerosis: fingolimod to the rescue?
Gillingwater TH
Br J Pharmacol; 2012 Feb; 165(4):858-60. PubMed ID: 21806598
[TBL] [Abstract][Full Text] [Related]
15. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
[TBL] [Abstract][Full Text] [Related]
16. Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice.
Lorvik KB; Bogen B; Corthay A
Blood; 2012 Mar; 119(9):2176-7. PubMed ID: 22383793
[No Abstract] [Full Text] [Related]
17. Azathioprine in multiple sclerosis.
Invernizzi P; Benedetti MD; Poli S; Monaco S
Mini Rev Med Chem; 2008 Aug; 8(9):919-26. PubMed ID: 18691149
[TBL] [Abstract][Full Text] [Related]
18. [New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod].
Komoly S
Ideggyogy Sz; 2012 Nov; 65(11-12):421-2. PubMed ID: 23289178
[No Abstract] [Full Text] [Related]
19. Effects of fingolimod in relapsing-remitting multiple sclerosis.
Sorensen PS
Lancet Neurol; 2014 Jun; 13(6):526-7. PubMed ID: 24685277
[No Abstract] [Full Text] [Related]
20. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Cohen JA; Chun J
Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
